Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.
Cronos Group Inc. reports developments for a global cannabis and cannabinoid company focused on consumer goods, cannabis research, technology and product development. Its brand portfolio includes Spinach®, PEACE NATURALS®, LIT® and Lord Jones®, with news often centered on product innovation across Canadian cannabis formats such as pre-rolls and vapes.
Recurring Cronos updates also cover operating and financial results, earnings conference calls, annual shareholder meetings, proxy and governance matters, capital-structure disclosures and public-company presentations. The company’s disclosures connect brand launches and R&D-driven product development with the financial and governance reporting of a Nasdaq- and TSX-listed cannabis issuer.
Cronos Group (NASDAQ: CRON) has issued a default status report as per NP 12-203 guidelines, following the announcement of a management cease trade order (MCTO) on November 9, 2021. The MCTO restricts trading by the CEO and CFO until the filing of the overdue Quarterly Report on Form 10-Q for Q3 2021, expected by February 18, 2022. However, the company confirms no material changes have occurred since the original announcement. Cronos Group remains committed to adhering to NP 12-203 guidelines while in default.
Cronos Group Inc. (NASDAQ: CRON) issued a default status report in compliance with NP 12-203, acknowledging a management cease trade order (MCTO) due to delays in filing its Quarterly Report for Q3 2021. Initially announced on November 9, 2021, the company has until February 18, 2022, to meet filing deadlines. The MCTO restricts trading for the CEO and CFO but not other shareholders. Cronos assures that no new material issues have arisen since the original announcement and commits to continue adhering to NP 12-203 guidelines until compliance is achieved.
Cronos Group (NASDAQ: CRON) has issued a default status report following its application for a management cease trade order (MCTO) due to an inability to file its Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. The MCTO, effective November 16, 2021, restricts trading by executives until necessary filings are made. Cronos anticipates filing by January 31, 2022, and reports no new material developments since the original announcement. The company is committed to compliance with alternative information guidelines while in default.
Cronos Group Inc. (NASDAQ: CRON) provides a default status report in compliance with NP 12-203 due to a management cease trade order (MCTO) stemming from its inability to file the Quarterly Report on Form 10-Q for Q3 2021 on time. The MCTO, issued on November 16, 2021, restricts trading by the CEO and CFO until the Required Filings are completed. The company aims to submit these filings by January 31, 2022, though this is not guaranteed. Cronos confirms no other significant changes since its initial announcement and will continue to comply with NP 12-203 guidelines.
Cronos Group Inc. (NASDAQ: CRON) has issued a default status report under NP 12-203 due to its inability to file the Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. Following the announcement on November 9, 2021, a management cease trade order (MCTO) was issued on November 16, 2021, restricting trades by the CEO and CFO. The company is working to meet the filing deadline, now expected by January 31, 2022, and confirms that there have been no material changes since the original announcement.
NatuEra has launched the Holiday Chill Bundle, a collection of five CBD wellness products aimed at alleviating holiday stress. The bundle features tinctures, capsules, and gummies, all containing Lemon Balm and varying levels of CBD sourced from sustainably grown hemp in Colombia's Andes Mountains. Priced at $99.99, the bundle offers a 23% discount compared to individual purchases and includes free shipping. NatuEra's products are manufactured in GMP-certified facilities, ensuring high quality and compliance with U.S. standards.
Aurora Cannabis (ACB) and 22nd Century Group (XXII) announced a licensing agreement with Cronos Group (CRON) to advance cannabinoid biosynthesis research. This non-exclusive deal aims to enhance the production of rare cannabinoids such as CBG, CBC, and CBN efficiently and with high purity. According to CEO Miguel Martin, the collaboration is a significant step towards commercializing cannabinoid products, which could benefit health and wellness applications. Aurora and 22nd Century also plan to enforce their intellectual property rights against infringements.
Cronos Group (NASDAQ: CRON) reports on its management cease trade order (MCTO) issued on November 16, 2021, due to the inability to file the Quarterly Report on Form 10-Q for the period ending September 30, 2021. The MCTO restricts trading for executive officers until the required filings are made. The company confirms no material changes since the original announcement and is committed to fulfilling alternative information guidelines. Cronos continues to work toward completing the necessary filings and emphasizes forward-looking statements about potential risks and uncertainties.
Beatrice Society has announced the formation of its Board of Directors, appointing Gary Yeoman as Chairman. The board includes seasoned professionals Lorne Gertner and Krisztián Tóth. Yeoman, previously at Voxtur Analytics and Altus Group, aims to build on recent acquisitions in psychedelics and wellness. Gertner co-founded Cannasat Therapeutics and has notable ties to the cannabis industry, while Tóth specializes in corporate finance. The board's expertise is expected to strengthen Beatrice's position in the growing psychedelic therapy market.
Cronos Group (NASDAQ: CRON) issued a default status report after applying for a Management Cease Trade Order (MCTO) due to an inability to file its Quarterly Report on Form 10-Q for the period ending September 30, 2021. The MCTO restricts trading by the CEO and CFO until filings are complete, but not for other shareholders. The company received a notice from Nasdaq regarding non-compliance with listing requirements. No material changes have occurred since the original announcement, and management is actively working on the required filings.